Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and …
Inhibition of wild-type EGFR is associated with cutaneous (and other) toxicities such as acneiform rash, stomatitis and paronychia, all of which may significantly impact patients' quality of life and result in treatment discontinuation and patient …
Read more on FierceBiotech
New drug shows promise against treatment-resistant non-small cell lung cancer
Current TKIs inhibit the normal EGFR as well as the mutant EGFR, causing acne-like skin rashes and paronychia – an inflammation of the folds of tissue around finger and toe nails – both of which can be very troublesome for patients." Patients with …
Read more on News-Medical.net
Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare …
Hi, good afternoon. My name is Ravi Mehrotra. I'm the Senior Biotechnology Analyst for Credit Suisse. It gives me great pleasure to introduce to you Pat Mahaffy, CEO of Clovis. I'm actually going to break them all to: A, we're going to do a little bit …
Read more on Seeking Alpha (registration)